Literature DB >> 3424264

Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.

J Banks1, P A Jenkins.   

Abstract

Drug sensitivity tests were performed for ethambutol, rifampicin, streptomycin, and isoniazid both alone and in paired combinations, on 16 strains of Mycobacterium avium intracellulare, seven strains of Mycobacterium xenopi, and eight strains of Mycobacterium malmoense. Most strains were resistant to the individual drugs, but all strains of M malmoense, 86% of M xenopi, and 31% of M avium intracellulare were completely suppressed by the lowest concentrations of ethambutol and rifampicin when the two drugs were combined in vitro. Streptomycin combined with ethambutol or with rifampicin in the lowest combined concentrations suppressed 50% and 62% respectively of strains of M malmoense. All strains of M xenopi were suppressed by the lowest combined concentrations of streptomycin with rifampicin. Combinations with isoniazid were less effective. It is postulated that similar effects in vivo might account for the satisfactory clinical response seen in patients with disease caused by these mycobacteria who have received treatment with combinations of standard antituberculosis drugs despite in vitro resistance to the individual agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3424264      PMCID: PMC461006          DOI: 10.1136/thx.42.11.838

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  4 in total

1.  The design of sensitivity tests on tubercle bacilli.

Authors:  J MARKS
Journal:  Tubercle       Date:  1961-09

2.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

3.  Pulmonary infection with Mycobacterium malmoense--a review of treatment and response.

Authors:  J Banks; P A Jenkins; A P Smith
Journal:  Tubercle       Date:  1985-09

4.  Pulmonary infection with mycobacterium xenopi: review of treatment and response.

Authors:  J Banks; A M Hunter; I A Campbell; P A Jenkins; A P Smith
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

  4 in total
  9 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

Review 2.  Treatment of pulmonary disease caused by opportunist mycobacteria.

Authors:  J Banks
Journal:  Thorax       Date:  1989-06       Impact factor: 9.139

3.  Recurrent mycobacterial infections in a patient with IL-12 deficiency.

Authors:  Matthew Buckland; Roshanara Ali; Graham Bothamley; David Lammas; Rainer Doffinger; Hilary Longhurst
Journal:  BMJ Case Rep       Date:  2009-12-01

4.  Treatment of Non-Tuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Mary Ann DeGroote; Jennifer R Honda; Michael M Chan; Shannon Kasperbauer; Nicholas D Walter; Edward D Chan
Journal:  Curr Treat Options Infect Dis       Date:  2016-10-11

5.  First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.

Authors: 
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

6.  Pulmonary Mycobacterium kansasii infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis.

Authors:  S A Evans; A Colville; A J Evans; A J Crisp; I D Johnston
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

7.  Pulmonary disease caused by Mycobacterium xenopi: the first case in Korea.

Authors:  Hye Yun Park; Won-Jung Koh; O Jung Kwon; Nam Yong Lee; Young Mog Shim; Young Kil Park; Gill Han Bai; Ho-Suk Mun; Bum-Joon Kim
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

8.  Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006.

Authors:  Jonathan E Moore; Michelle E Kruijshaar; L Peter Ormerod; Francis Drobniewski; Ibrahim Abubakar
Journal:  BMC Public Health       Date:  2010-10-15       Impact factor: 3.295

9.  Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.

Authors:  Claire Andréjak; Deepak V Almeida; Sandeep Tyagi; Paul J Converse; Nicole C Ammerman; Jacques H Grosset
Journal:  J Antimicrob Chemother       Date:  2012-11-05       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.